|
Market Closed -
Nasdaq
21:00:00 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 1.970 USD | -0.51% |
|
-2.48% | +43.80% |
Company Valuation: Allogene Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,126 | 907.1 | 540.2 | 446.6 | 307.9 | 680.6 | - | - |
| Change | - | -57.34% | -40.45% | -17.32% | -31.06% | 121.07% | - | - |
| Enterprise Value (EV) 1 | 1,317 | 330.6 | 91.47 | 234.8 | 347 | 484.1 | 530.4 | 349.5 |
| Change | - | -74.89% | -72.33% | 156.69% | 47.8% | 39.49% | 9.58% | -34.11% |
| P/E | -7.89x | -2.71x | -1.54x | -1.61x | -1.57x | -3.26x | -3.07x | -3.52x |
| PBR | 2.32x | 1.36x | 1.06x | 1.07x | 1.07x | 1.7x | 3.42x | 1.53x |
| PEG | - | -0.1x | 0.16x | 0x | 0x | 0.1x | -0.48x | 0.3x |
| Capitalization / Revenue | 55.2x | 3,733x | 5,686x | 20,300x | - | 200x | 56.3x | 8.04x |
| EV / Revenue | 34.2x | 1,361x | 963x | 10,673x | - | 142x | 43.9x | 4.13x |
| EV / EBITDA | -5.37x | -1.03x | -0.29x | -0.96x | -1.76x | -2.42x | -2.21x | -1.29x |
| EV / EBIT | -5.15x | -0.99x | -0.28x | -0.91x | -1.66x | -2.43x | -2.28x | -1.6x |
| EV / FCF | -6.38x | -1.46x | -0.38x | -1.17x | -2.32x | -3.83x | -3.63x | -2.78x |
| FCF Yield | -15.7% | -68.3% | -262% | -85.6% | -43.1% | -26.1% | -27.5% | -36% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.89 | -2.32 | -2.09 | -1.32 | -0.87 | -0.6036 | -0.642 | -0.5596 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.49 | 0.243 | 0.095 | 0.022 | - | 3.4 | 12.09 | 84.64 |
| EBITDA 1 | -245.3 | -321.2 | -313.5 | -243.8 | -197 | -200.2 | -239.7 | -271.5 |
| EBIT 1 | -255.8 | -335.4 | -327.7 | -257.5 | -209.3 | -199.1 | -232.9 | -218.3 |
| Net income 1 | -257 | -332.6 | -327.3 | -257.6 | -190.9 | -185.1 | -219.8 | -212.4 |
| Net Debt 1 | -809.5 | -576.5 | -448.7 | -211.8 | 39.16 | -196.5 | -150.2 | -331.1 |
| Reference price 2 | 14.920 | 6.290 | 3.210 | 2.130 | 1.370 | 1.970 | 1.970 | 1.970 |
| Nbr of stocks (in thousands) | 142,516 | 144,210 | 168,277 | 209,672 | 224,730 | 345,491 | - | - |
| Announcement Date | 23/02/22 | 28/02/23 | 14/03/24 | 13/03/25 | 12/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.26x | 142.38x | -2.42x | -.--% | 681M | |
| 20.25x | 7.04x | 14.2x | 1.45% | 67.98B | |
| 36.9x | 9.64x | 29.44x | 0.04% | 64.94B | |
| -77.3x | 14.92x | -71.95x | -.--% | 27.58B | |
| 29.69x | 6.35x | 16.48x | -.--% | 25.74B | |
| -15.85x | 6.12x | -7.7x | -.--% | 26.06B | |
| 27.41x | 5.13x | 17.06x | -.--% | 20.09B | |
| 49.41x | 18.23x | 36.98x | 0.31% | 17.16B | |
| 1289.22x | 37.23x | 812.54x | -.--% | 14.92B | |
| 18.23x | 5.44x | 12.69x | -.--% | 14.62B | |
| Average | 137.47x | 25.25x | 85.73x | 0.18% | 27.98B | |
| Weighted average by Cap. | 81.81x | 10.68x | 51.47x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALLO Stock
- Valuation Allogene Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
